Published on : Jun 06, 2017
Albany, New York, June 06, 2017: The comprehensive report on yellow fever therapeutics pipeline landscape offers in-depth insights into the key market dynamics, potential of various molecule types, key trends and lucrative avenues, and major advancements in therapeutics. The research evaluates recent drug development initiatives of key players on the competitive dynamics by taking a closer look at recent innovations in finding better drug target and their mechanism of action. Research in finding new routes of administration for the delivery of therapies of yellow fever are covered in the study. The report assesses the pharmacological impact of major therapeutics expected to affect the strategies of pharmaceutical and biotechnology companies.
The report highlights the product portfolios of various players in various developed and developing regions. The growing need for finding effective therapies and vaccines for yellow fever in various regions, especially where the diseases has been endemic, is a key factor propelling developments in drug pipeline of yellow fever. According to a recent fact sheet by the World Health Organization (WHO) last updated in 2016, 34 countries in Africa and 13 in Central and South America have regions where the disease is endemic, which has spurred developments in drug pipeline for yellow fever.
Rising concerns in countries, such as North America and Europe, at the risk of importation of yellow fever due to the influx of people coming from endemic areas have stimulated demand for yellow fever vaccination. This has further stimulated research in yellow fever therapeutics pipeline. Large investments in clinical trials in various regions for developing the therapeutic pipeline for yellow fever are expected to create exciting opportunities in the market. However, the yellow fever epidemic in Africa indicates several gaps in vaccine pipeline for yellow fever. This has alerted several the government and public health organizations. This has led them to make provisioning for emergency vaccine supply pipeline, apart from the continued supply of vaccines in order to successfully control the outbreak.
Click to get more details with TOC in a PDF Format: http://www.researchmoz.us/enquiry.php?type=S&repid=1070416
The recent outbreak of yellow fever epidemic in densely populated states of Brazil has been a cause for large concern for the government there, catalyzing developments of new vaccines in yellow fever pipeline. Furthermore, the mounting concern of disease outbreak has recently led the WHO to recommend yellow fever vaccine for travelers visiting various parts of Rio de Janeiro and Sao Paulo. This is further expected to accentuate the demand for vaccines and favorably impact the therapeutics pipeline in the coming years.
The inefficiency in manufacturing of vaccines in developed nations such as the U.S. recently led to a marked shortage of vaccines. This will further encourage several pharmaceutical and biotechnology players to expand their therapeutics pipeline. The development of a bio-better monoclonal antibody product is expected to bode well for the yellow fever therapeutics pipeline.
Major market players profiled in the report include Sihuan Pharmaceutical Holdings Group Ltd., NewLink Genetics Corporation, Valneva SE, Johnson & Johnson, iBioPharma Inc., Ennaid Therapeutics, Ennaid Therapeutics, Bavarian Nordic A/S, and Arno Therapeutics Inc.
To order report Call USA – Canada Toll Free: 866-997-4948 or send an email on email@example.com